2026-06-07T23:46:42Zhttps://docta.ucm.es/rest/oai/request
oai:docta.ucm.es:20.500.14352/70542024-10-11T17:12:11Zcom_20.500.14352_14col_20.500.14352_15
Docta Complutense author Zaballos García, Matilde author Power, Mercedes author Canal Alonso, María Iluminada author González Nicolás González, María Ángeles author Vasquez Jimenez, Wenceslao author Lozano Lominchar, Pablo author Cabrerizo Torrente, Pilar author Palencia García, Natividad author Gago Quiroga, Susana author Ginel Feito, María Dolores author Jiménez, Consuelo author Lázaro Fernández, Alberto author González Bayón, Luis 2023-06-17T08:25:17Z 2023-06-17T08:25:17Z 2021-01-27 Zaballos M, Power M, Canal-Alonso MI, González-Nicolás MÁ, Vasquez-Jimenez W, Lozano-Lominchar P, et al. Effect of Cilastatin on Cisplatin-Induced Nephrotoxicity in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy. IJMS 2021;22:1239. https://doi.org/10.3390/ijms22031239. 1422-0067 10.3390/ijms22031239 https://hdl.handle.net/20.500.14352/7054 https://doi.org/10.3390/ijms22031239 https://www.mdpi.com/1422-0067/22/3/1239/htm Cisplatin is one of the most widely used chemotherapeutic agents in oncology, although its nephrotoxicity limits application and dosage. We present the results of a clinical study on prophylaxis of cisplatin-induced nephrotoxicity in patients with peritoneal carcinomatosis undergoing cytoreduction and hyperthermic intraperitoneal intraoperative chemotherapy (HIPEC-cisplatin). Prophylaxis was with imipenem/cilastatin. Cilastatin is a selective inhibitor of renal dehydropeptidase I in the proximal renal tubule cells that can reduce the nephrotoxicity of cisplatin. Unfortunately, cilastatin is not currently marketed alone, and can only be administered in combination with imipenem. The study has a retrospective part that serves as a control (n = 99 patients receiving standard surgical prophylaxis) and a prospective part with imipenem/cilastatin prophylaxis corresponding to the study group (n = 85 patients). In both groups, we collected specific data on preoperative risk factors of renal damage, fluid management, hemodynamic control, and urine volume during surgery (including the hyperthermic chemotherapy perfusion), as well as data on hemodynamic and renal function during the first seven days after surgery. The main finding of the study is that cilastatin may exert a nephroprotective effect in patients with peritoneal carcinomatosis undergoing cytoreduction and hyperthermic intraperitoneal cisplatin perfusion. Creatinine values remained lower than in the control group (ANOVA test, p = 0.037). This translates into easier management of these patients in the postoperative period, with significantly shorter intensive care unit (ICU) and hospital stay. eng Atribución 3.0 España Effect of Cilastatin on Cisplatin-Induced Nephrotoxicity in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy journal article URL https://docta.ucm.es/bitstreams/e5cdc8b8-c464-4e11-acfc-ef9053af6c7d/download File MD5 308f57e254a4d512ed11408afbac41dc 1422167 application/pdf ijms-22-01239.pdf